Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vistusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PFKP | Q01813 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vistusertib SCHEMBL20734874 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL1214881 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL22449928 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29350053 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL290672 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29353400 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449835 | 0.95 | MTOR (0.90) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL10225658 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22858573 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22030452 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705301-A2 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119925616-A | CD20 therapy, CD22 therapy and combination therapy with CD19 Chimeric Antigen Receptor (CAR) expressing cells | 诺华股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4499101-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | Merck Sharp & Dohme LLC (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4476220-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118946359-A | Pharmaceutical combinations of amino-pyrrolopyrimidinone compounds and methods of use | 默沙东有限责任公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024229442-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229444-A2 | MUTANT KRAS INHIBITORS AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-116478927-A | Human mesothelin chimeric antigen receptor and application thereof | 诺华股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023102201-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-106459989-B | Human mesothelin chimeric antigen receptor and uses thereof | 诺华股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-115645534-A | Novel compositions and methods for treating or preventing skin disorders | 德雷克塞尔大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20220387486-A1 | NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| CN-114958764-A | CD20 therapy, CD22 therapy, and combination therapy with CD19 Chimeric Antigen Receptor (CAR) -expressing cells | 诺华股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114621969-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-109689051-B | Use of inhibitors of mitochondrial activity for the treatment of acute myeloid leukemia with poor prognosis | 蒙特利尔大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-114107424-A | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | 诺华股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387486-A1 | NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN | CD22, CD2, CD209 | MTOR 4443/4885PIK3CA 3127/4885PIK3CD 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.